Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Investigating the Clinical Consequences of Flutemetamol-PET-scanning

Authors not listed

University of Zurich · 2015

Abstract

The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force. In these subjects the impact of a Flutemetamol (Vizamyl)-Positron-Emission-Tomography -Scan (PET) on clinical management and disease course will be studied over 6 months.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-02 MST

Cite this

APA
Anonymous. (2015). Investigating the Clinical Consequences of Flutemetamol-PET-scanning. <em>University of Zurich</em>. https://clinicaltrials.gov/study/NCT02353949
Vancouver
Anonymous. Investigating the Clinical Consequences of Flutemetamol-PET-scanning. University of Zurich. 2015.
BibTeX
@misc{anon2015Invest, title = {Investigating the Clinical Consequences of Flutemetamol-PET-scanning}, author = {Anonymous}, journal = {University of Zurich}, year = {2015}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings